Experience

Cidara Therapeutics Announces Concurrent Reacquisition of IP Rights to CD388, $240 Million PIPE Financing

May 1, 2024

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.

Read more

Related contacts

Charles Bair
Partner, San Diego
Jane Adams
Partner, San Diego
Barbara Borden
Partner, San Diego
Megan Browdie
Partner, Washington, DC
Daniel I. Goldberg
Partner, New York
Aaron Pomeroy
Partner, Colorado
Richard Segal
Partner, New York
Francis Wheeler
Partner, Colorado
Sharon Connaughton
Special Counsel, Washington, DC
Asa Henin
Special Counsel, San Diego
Alexis Guillermo Buz
Associate, San Diego
Gaël Y. Hagan
Associate, Colorado
Michelle Hunt
Associate
Edmond Lay
Associate, San Diego
Kyrsten Lundh
Associate, San Diego
Jayden Martinez
Associate, Colorado
Amanda Pacheco
Associate, Palo Alto
Valerie Sapozhnikova
Associate, Los Angeles
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

Cidara Enters Collaboration With Janssen

April 27, 2021

Cooley advised biotechnology company Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. Partners Jane Adams and Tanisha James led the Cooley team advising Cidara.

Under the terms of the collaboration, Cidara will be responsible for the development and manufacturing of the first influenza antiviral conjugates, CD388, into the clinic and through phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. Cidara will receive a $27 million upfront payment and will be eligible to receive up to $753 million in budgeted research and development funding and in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales. 

Read more

Related contacts

Jane Adams
Partner, San Diego
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Cidara Enters Collaboration With Janssen

April 26, 2021

Cooley advised biotechnology company Cidara Therapeutics on its exclusive worldwide licensing and collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize Cidara’s Cloudbreak antiviral conjugates for the prevention and treatment of seasonal and pandemic influenza. Partners Jane Adams and Tanisha James led the Cooley team advising Cidara.

Read more

Related contacts

Jane Adams
Partner, San Diego
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Ionis Pharmaceuticals Enters Collaboration Agreement with Janssen Biotech

January 29, 2015

San Diego – Cooley advised Ionis Pharmaceuticals on a global collaboration, option and license agreement with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the GI tract.

Pursuant to the agreement, Ionis will receive $35 million in up-front payments for three programs, including a payment to initiate human lead optimization on the first collaboration target. Isis is also eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for the programs.

Ionis is the leader in antisense drug discovery and development, exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.

Partner Jane Adams, a member of Cooley's life sciences partnering and licensing group, led the Cooley team that advised Ionis Pharmaceuticals on the collaboration.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Related contacts

Jane Adams
Partner, San Diego

Related Practices & Industries

Admissions and credentials

California

Rankings and accolades

The Best Lawyers in America: Biotechnology Law and Life Sciences

San Diego Daily Transcript: Top San Diego County Attorney, IP transactional (2010)

San Diego Daily Transcript: Top San Diego County Attorney, corporate transactional (2007)

Lawdragon 500: New Stars, New Worlds (2006)

Lawdragon 3000: Leading Lawyer in America (2006)

Memberships and affiliations

American Bar Association (ABA)

San Diego County Bar Association